Cargando…
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial
BACKGROUND: CombiRx was a randomized, double-blind, placebo-controlled phase 3 trial in treatment-naive relapsing-remitting multiple sclerosis (RRMS) patients randomized to intramuscular interferon beta-1a (IM IFN beta-1a), glatiramer acetate (GA), or both therapies. OBJECTIVE: This analysis investi...
Autores principales: | Cutter, Gary, Rudick, Richard A, de Moor, Carl, Singh, Carol M, Fisher, Elizabeth, Koster, Thijs, Lublin, Fred D, Wolinsky, Jerry S, McFarland, Henry, Jacobson, Steven, Naylor, Maria L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150429/ https://www.ncbi.nlm.nih.gov/pubmed/37139460 http://dx.doi.org/10.1177/20552173231169463 |
Ejemplares similares
-
Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023) -
The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis
por: Ben-Zacharia, Aliza Bitton, et al.
Publicado: (2021) -
Regional Gray Matter Atrophy in Relapsing Remitting Multiple Sclerosis: Baseline Analysis of Multi-Center Data
por: Datta, Sushmita, et al.
Publicado: (2015) -
Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study()
por: Narayana, Ponnada A., et al.
Publicado: (2012) -
Neurofilament light chain predicts disease activity in relapsing-remitting MS
por: Varhaug, Kristin N., et al.
Publicado: (2017)